Key result
In Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors, the incidence rate of vascular adverse events was 9.1 per 1,000 person-years, and the Hisayama score effectively stratified high-risk patients.
Why the study?
Patients with CML on TKI therapy face increased risk of vascular adverse events, but appropriate and effective risk assessment tools for TKI treatment have long been anticipated.
Do the Hisayama and Framingham scores effectively stratify the risk of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors?
Cohort (n=626)
Yes
Do the Hisayama and Framingham scores effectively stratify the risk of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors?
The Hisayama and Framingham scores effectively stratify the risk of vascular adverse events in Japanese patients with CML treated with TKIs, highlighting smoking and hypertension as prominent modifiable risk factors.
Answers are grounded in this paper and cite their sources.
May support VAE risk stratification in TKI-treated CML; hypothesis-generating and needs prospective validation before practice change.
BACKGROUND: Tyrosine kinase inhibitor (TKI) therapy improves the overall survival of patients with chronic myeloid leukemia (CML). However, the risk of vascular adverse events (VAEs) in these patients is reported to be higher than that in healthy individuals, because of both CML itself and the effects of TKIs. Appropriate and effective VAE risk assessment tools for TKI treatment have long been anticipated. METHODS: Here, we investigated the usefulness of a newly developed VAE risk assessment tool, the Hisayama score, and presented data on the clinical characteristics of VAEs in Japanese patients with CML based on an analysis of a real-world, large-cohort database. RESULTS: Patients with CML who developed VAEs were evaluated using three VAE risk assessment tools. Forty-four VAEs were reported in 41 out of 626 patients with CML, with three patients developing multiple VAEs during the observation period. There were 16 cases of cerebral infarction, 19 of ischemic heart disease, and nine of peripheral artery occlusive disease, with rates per 1,000 person-years of 3.23, 3.84, and 2.02, respectively. The Framingham and Hisayama scores stratified high-risk patients with VAEs more effectively than the SCORE chart. Smoking and hypertension are prominent risk factors for VAEs. CONCLUSIONS: Our results clearly demonstrate that the Hisayama score can be used to evaluate VAE risk in high-risk patients. Selecting appropriate TKIs based on each patient risk, smoking cessation, and blood pressure control may contribute to selecting appropriate TKIs and managing VAE risk.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2025) conducted a cohort in Chronic myeloid leukemia (n=626). Tyrosine kinase inhibitors vs. General population was evaluated on Incidence of vascular adverse events. In Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors, the incidence rate of vascular adverse events was 9.1 per 1,000 person-years, and the Hisayama score effectively stratified high-risk patients.
Synapse has enriched 10 related papers. Consider them for comparative context: